Literature DB >> 12160092

Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.

A Giełdoń1, R Kaźmierkiewicz, R Slusarz, J Ciarkowski.   

Abstract

The nonapeptide hormones arginine vasopressin (CYFQNCPRG-NH2, AVP) and oxytocin (CYIQNCPLG-NH2, OT), control many essential functions in mammals. Their main activities include the urine concentration (via stimulation of AVP V2 receptors, V2R, in the kidneys), blood pressure regulation (via stimulation of vascular V1a AVP receptors, V1aR), ACTH control (via stimulation of V1b receptors, V1bR, in the pituitary) and labor and lactation control (via stimulation of OT receptors, OTR, in the uterus and nipples, respectively). All four receptor subtypes belong to the GTP-binding (G) protein-coupled receptor (GPCR) family. This work consists of docking of YM087, a potent non-peptide V1aR and V2R - but not OTR - antagonist, into the receptor models based on relatively new theoretical templates of rhodopsin (RD) and opiate receptors, proposed by Mosberg et al. (Univ. of Michigan, Ann Arbor, USA). It is simultaneously demonstrated that this RD template satisfactorily compares with the first historical GPCR structure of bovine rhodopsin (Palczewski et al., 2000) and that homology-modeling of V2R, V1aR and OTR using opiate receptors as templates is rational, based on relatively high (20-60%) sequence homology among the set of 4 neurophyseal and 4 opiate receptors. YM087 was computer-docked to V1aR, V2R and OTR using the AutoDock (Olson et al., Scripps Research Institute, La Jolla, USA) and subsequently relaxed using restrained simulated annealing and molecular dynamics, as implemented in AMBER program (Kollman et al., University of California, San Francisco, USA). From about 80 diverse configurations, sampled for each of the three ligand/receptor systems, 3 best energy-relaxed complexes were selected for mutual comparisons. Similar docking modes were found for the YM087/V1aR and YM087/V2R complexes, diverse from those of the YM087/OTR complexes, in agreement with the molecular affinity data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12160092     DOI: 10.1023/a:1015905822671

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  37 in total

1.  Movement of retinal along the visual transduction path.

Authors:  B Borhan; M L Souto; H Imai; Y Shichida; K Nakanishi
Journal:  Science       Date:  2000-06-23       Impact factor: 47.728

2.  A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor.

Authors:  M Thibonnier; P Coles; D M Conarty; C L Plesnicher; M Shoham
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

Review 3.  Discovery, development, and some uses of vasopressin and oxytocin antagonists.

Authors:  M Manning; W H Sawyer
Journal:  J Lab Clin Med       Date:  1989-12

4.  The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions.

Authors:  B Mouillac; B Chini; M N Balestre; J Elands; S Trumpp-Kallmeyer; J Hoflack; M Hibert; S Jard; C Barberis
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

Review 5.  G-Protein coupled receptors: models, mutagenesis, and drug design.

Authors:  J A Bikker; S Trumpp-Kallmeyer; C Humblet
Journal:  J Med Chem       Date:  1998-07-30       Impact factor: 7.446

6.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors.

Authors:  J M Baldwin; G F Schertler; V M Unger
Journal:  J Mol Biol       Date:  1997-09-12       Impact factor: 5.469

7.  Automated method for modeling seven-helix transmembrane receptors from experimental data.

Authors:  P Herzyk; R E Hubbard
Journal:  Biophys J       Date:  1995-12       Impact factor: 4.033

8.  Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis.

Authors:  F Fanelli; P Barbier; D Zanchetta; P G de Benedetti; B Chini
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

9.  The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints.

Authors:  I D Pogozheva; A L Lomize; H I Mosberg
Journal:  Biophys J       Date:  1997-05       Impact factor: 4.033

10.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

Authors:  B Chini; B Mouillac; Y Ala; M N Balestre; S Trumpp-Kallmeyer; J Hoflack; J Elands; M Hibert; M Manning; S Jard
Journal:  EMBO J       Date:  1995-05-15       Impact factor: 11.598

View more
  3 in total

1.  The 3D structure of the binding pocket of the human oxytocin receptor for benzoxazine antagonists, determined by molecular docking, scoring functions and 3D-QSAR methods.

Authors:  Balázs Jójárt; Tamás A Martinek; Arpád Márki
Journal:  J Comput Aided Mol Des       Date:  2005-05       Impact factor: 3.686

2.  Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Antonella Vetuschi; Julie Venter; Roberta Sferra; Luigi Pannarale; Francesca Olivero; Guido Carpino; Gianfranco Alpini; Paolo Onori; Eugenio Gaudio
Journal:  Lab Invest       Date:  2016-08-29       Impact factor: 5.662

3.  Identification of antagonists to the vasotocin receptor sub-type 4 (VT4R) involved in stress by molecular modelling and verification using anterior pituitary cells.

Authors:  Srinivas Jayanthi; Seong Wook Kang; Daniel Bingham; Brian A Tessaro; Thallapuranam K Suresh Kumar; Wayne J Kuenzel
Journal:  J Biomol Struct Dyn       Date:  2013-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.